Experience our latest technological development
and innovations by sharing our projects and successes.
We want to share with you each step
of our growth.
Follow us on social networks.
Let’s meet during one of our upcoming congress.
Jun. 26, 2019 - PI-RADS, what's new!? - New elements to improve detection, localization, characterization and risk stratification
During this webinar we will discuss the new features of this standard in the image data acquisition, the interpretation criteria and the role of the biparametric MRI.
Watch the replay >
Intrasense is pleased to announce its participation in the congress of the Société d'Imagerie de la Femme, in Ajaccio from September 17 to 19. Learn more >
Intrasense provides an update on its development strategy following its successful capital increase in June 2021. Learn more >
Jun 22, 2021 - Intrasense: successful Rights Issue with €4.9 million raised
Intrasense today announced the success of its capital increase through the issuance of new shares (“New Shares”) with shareholders’ preferential subscription rights, for which subscriptions took place between May 28 and June 15, 2021 (the “Rights Issue”). Learn more >
Intrasense today announces the publication of its annual financial report for the financial year ended on December 31, 2020. Learn more >
Apr. 08, 2021 - Intrasense announces the referencing of its Myrian® platform with Vidi, first cooperative network of medical imaging groups in France
Intrasense and Vidi, the leading cooperative network of medical imaging groups in France, signed an agreement on January 30th, 2021 to reference Myrian® solutions. Learn more >
Apr. 01, 2021 - New Myrian platform launch, enriched with many new clinical features dedicated to stroke, breast cancer and cardiovascular pathologies
Intrasense is pleased to present the new version 2.9, with a focus on new clinical features. Learn more >
Jan. 29, 2021 - Half year report of Intrasense’s liquidity contract signed with TSAF – Tradition Securities And Futures
Intrasense announces the publication of its half year liquidity contract signed with TSAF – Tradition Securities And Futures. Learn more >
Intrasense is pleased to present the new version 2.8 of its visualization platform with many new features, from clinical applications to improved workflow. Learn more >
Oct. 08, 2020 - Partial renewal and strengthening of the board of directors
Intrasense announces following a Board meeting on October 8th, 2020, a partial renewal and strengthening of its composition. Michèle Lesieur is coopted as administrator and appointed Chairman of the Board. Anne Larpin is coopted as administrator of the company. The ratification of these cooptations will be submitted to the next ordinary general meeting. Learn more >
Apr. 21, 2020 - CE marking for the CT protocol dedicated to COVID-19
Intrasense announces that the scanner reading protocol dedicated to COVID-19 has obtained its CE marking as a world premiere. Learn more >
Intrasense combines its technological expertise with the clinical expertise of the Compagnie de Télémédecine (CTM Groupe) by deploying to all of the group's radiotherapy specialists the new scanner reading protocol dedicated to COVID-19. Learn more >
Dec. 19, 2019 - Intrasense™ announces the end of the BCS financing contract
Intrasense™ announces the end of the BCS (Bond Convertible into Shares) financing contract concluded with the Luxembourgish fund European High Growth Opportunities Securitization Fund (EHGO). Learn more >
Nov. 19, 2019 - Intrasense™ showcases innovative solutions at RSNA 2019
Artificial intelligence will be highlighted on Intrasense™ booth (#6956). The new version of Myrian® platform enabling artificial intelligence to truly be embedded into the daily workflow and clinical routine.Learn more >
Sep. 30, 2019 - Intrasense™ presents its innovations at JFR 2019 show
All innovations will be presented at JFR 2019 on the Intrasense ™ booth (# 213A). The new version of Myrian® as well as the XP-Mammo application will be display.Learn more >
Jul. 11, 2019 - 2019 Half -Year Results: strong growth in all financial indicators and convertible bonds contract suspension maintained
Achieving a positive Net Income within this first 2019 semester validates the strategic choices set by the new governance in 2018, generating profits for the first half of 2019 financial year.Learn more >
Apr. 29, 2019 - Intrasense™ and Radboudumc sign a multiyear partnership, deploying Myrian® XP-Prostate application as a worldwide reference
Myrian® XP Prostate, the new reference tool for worldwide prostate experts.Learn more >
Feb. 20, 2019 - Intrasense and 12 Sigma unveil their innovative artificial intelligence solutions at the ECR 2019 congress
Presentation of 3 innovative products based on Myrian® technology Learn more >
suspension of the automatic drawdowns of bounds convertible into shares (« OCA »), initially planned in the contract signed on August 27, 2018.
Learn more >
February 27-March 3, 2019
Vienna - AUSTRIA
Artificial Intelligence Hall - Booth #AI-8
December 01-05, 2019
Mc Cormick Place - Chicago - USA